Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer

Cochrane Database of Systematic Reviews

Volumn 2011, Issue 11, 2011, Pages

  Jaaback, Kenneth ^a   Johnson, Nick ^b   Lawrie, Theresa A ^c  

^a JOHN HUNTER HOSPITAL   (Australia)

^b ROYAL UNITED HOSPITALS BATH NHS FOUNDATION TRUST   (United Kingdom)

^c ROYAL UNITED HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; DISEASE ASSESSMENT; DISEASE FREE INTERVAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; OUTCOME ASSESSMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PERITONEAL CAVITY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; DISEASE FREE SURVIVAL; FEMALE; INFUSION; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; METHODOLOGY; MORTALITY; OVARY TUMOR;

ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INFUSIONS, PARENTERAL; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84860794367     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD005340.pub3     Document Type: Review

References (47)

1. Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III. ovarian cancer. New England Journal of Medicine 1996;335(26):1950-5.
2. Gadducci A, Carnino F, Chiara S, Brunetti I, Tanganelli L, Romanini A, et al. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomised trial of the Gruppo Oncologico Nord-Ovest. Gynecologic Oncology 2000;76(2):157-62.
3. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. The New England Journal of Medicine 2006;354(1):34-43.
4. Armstrong DK, Bundy BN, Baergen R, Lele SB, Copeland LJ, Walker, et al. Randomized phase III. study of intravenous (IV) paclitaxel and cisplatin versus IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III. epithelial ovarian cancer (OC): a Gynecologic Oncology Group trial (GOG 172). Proceedings of the American Society of Clinical Oncology. 2002; Vol. 21:201a.
5. Krivak TC, Tian C, Rose GS, Armstrong DK, Maxwell GL. A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III. optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy: an analysis of patients enrolled in GOG 172. Gynecologic Oncology 2009;115(1):81-5.
6. Lesnock J, Darcy K, Tian C, Gallion H, DeLoia J, Armstrong D, et al. Association between reduced BRCA1 expression and survival in patients with sporadic epithelial ovarian cancer treated with intraperitoneal versus intravenous cisplatin and paclitaxel: A Gynecologic Oncology Group study. Gynecologic Oncology 2010;116(Conference Publication: 3 Suppl.1):S3-S4.
7. Walker JL, Armstrong DK, Huang HQ, Fowler J, Webster K, Burger RA, et al. Intraperitoneal catheter outcomes in a phase III. trial of intravenous versus intraperitoneal chemotherapy in optimal stage III. ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecologic Oncology 2006;100(1):27-32.
8. Wenzel LB, Huang HQ, Armstrong DK, Walker JL, Cella D, and Gynecologic Oncology Group. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology 2007;25(4):437-43.
9. Kirmani S, Braly PS, McClay EF, Saltzstein SL, Plaxe SC, Kim S, et al. A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer. Gynecologic Oncology 1994;54(3):338-44.
10. Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, et al. Phase III. trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III. ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. Journal of Clinical Oncology 2001;19(4):1001-7.
11. Polyzos A, Tsavaris N, Kosmas C, Giannikos L, Katsikas M, Kalahanis N, et al. A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III. ovarian cancer. Oncology 1999;56(4):291-6.
12. Yen MS, Juang CM, Lai CR, Chao GC, Ng HT, Yuan CC. Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III. optimally cytoreduced epithelial ovarian cancer. International Journal of Gynecology and Obstetrics 2001;72(1):55-60.
13. Yen MS, Twu NF, Lai CR, Horng HC, Chao KC, Juang CM. Importance of delivered cycles and nomogram for intraperitoneal chemotherapy in ovarian cancer. Gynecologic Oncology 2009;114(3):415-9.
14. Zylberberg B, Ravina JH, Salat-Baroux J, Dormont D, Lipp B, Guillet JL. Polychemotherapy of ovarian cancer via combined intravenous and intraperitoneal routes. Technic and preliminary results [Polychimiotherapie des cancers de l'ovaire par voie mixte intraveineuse et intraperitoneale. Technique et resultats preliminaires]. Journal de Gynécologie Obstétrique et Biologie de la Reproduction 1986;15(5):671-6.
15. Piccart MJ, Floquet A, Scarfone G, Willemse PH, Emerich J, Vergote I, et al. Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomised phase III. study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. International Journal of Gynecological Cancer 2003;13 Suppl 2:196-203.
16. GOG-0252. Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II, Stage III., or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer. ClinicalTrials.gov Identifier: NCT00951496.
17. Aotani E, Kukino S, Nonaka M, Nagao S, Fujiwara K. First attempt of large phase III. oncology trial using Japanese new trial evaluation system, the evaluation system of investigational medical care. Japanese Pharmacology and Therapeutics 2010;38(Suppl.1):S59-S64.
18. Fujiwara K, Aotani E, Hamano T, Nagao S, Yoshikawa H, Sugiyama T, et al. A randomized phase II/III. trial of 3 weekly intraperitoneal versus intravenous carboplatin in combination with intravenous weekly dose-dense paclitaxel for newly diagnosed ovarian, fallopian tube and primary peritoneal cancer. Japanese Journal of Clinical Oncology 2011;41(2):278-82.
19. Secondary debulking surgery +/- hyperthermic intraperitoneal chemotherapy in stage III. ovarian cancer. http://www.bioportfolio.com/resources/trial/102235/Secondary-Debulking-Surgery-Hyperthermic-Intraperitoneal-Chemotherapy-In-Stage-Iii-Ovarian-Cancer.html.
20. Secondary debulking surgery +/- hyperthermic intraperitoneal chemotherapy in stage III. ovarian cancer. http://www.cancer.gov/clinicaltrials/search/view?cdrid=533399&version=HealthProfessional&protocolsearchid=9267648.
21. Mackay HJ, Provencheur D, Heywood M, Tu D, Eisenhauer EA, Oza AM. Phase II/III. study of intraperitoneal chemotherapy after neoadjuvant chemotherapy for ovarian cancer: NCIC CTG OV.21. Current Oncology 2011;18(2):84-90. [: NCT00993655]
22. American Cancer Society. Detailed Guide: Ovarian Cancer. What are the key statistics about ovarian cancer?. American Cancer Society, 2005.
23. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. The New England Journal of Medicine 2006;354(1):34-43.
24. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. Journal of Clinical Oncology 2002;20:1248-59.
25. Burghardt E, Girardi F, Lahousen M, Tamussino K, Stettner H. Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer. Gynecologic Oncology 1991;40 (2):103-6.
26. Chi D, Dao F, Ferguson S, Sabbatini P, Hensley M, Konner J, et al. Analysis of progression-free survival, tolerability and toxicity in patients with stage III. ovarian, tubal and peritoneal carcinoma treated with an outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin. Gynecologic Oncology 2010;Conference Publication: 116(3 Suppl 1):S123.
27. Deraco M, Kusamura S, Virzì S, Puccio F, Macrì A, Famulari C, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: Multi-institutional phase-II. trial. Gynecologic Oncology 2011;122(2):215-20.
28. du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, et al. A randomised clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of the National Cancer Institute 2003;95(17):1320-9.
29. Fujiwara 2008. Can carboplatin replace cisplatin for intraperitoneal use?. International Journal of Gynecological Cancer 2008;18(Suppl 1):29-32.
30. Fujiwara K, Nagao S, Kigawa J, Noma J, Akamatsu N, Miyagi Y, et al. Phase II. study of intraperitoneal carboplatin with intravenous paclitaxel in patients with suboptimal residual epithelial ovarian or primary peritoneal cancer: A Sankai Gynecology Cancer Study Group Study. International Journal of Gynecological Cancer 19;5:834-7.
31. Gray HJ, Shah CA, Swensen RE, Tamimi HK, GoffBA. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer. Gynecologic Oncology 2010;116(3):340-4.
32. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org.
33. Howell SB, Pfeifle CL, Wung WE, Olshen RA, Lucas WE, Yon JL, et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Annals of Internal Medicine 1982;97:845-51.
34. Jones RB, Myers CE, Guarino AM, Dedrick RL, Hubbard SM, DeVita VT. High volume intraperitoneal chemotherapy ("belly bath") for ovarian cancer. Pharmacologic basis and early results. Cancer Chemotherapy and Pharmacology 1978;1(3):161-6.
35. Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009;374:1331-8.
36. Lopez JA, Krikorian JG, Reich SD, Smyth RD, Lee FH, Issell BF. Clinical pharmacology of intraperitoneal cisplatin. Gynecologic Oncology 1985;20(1):1-9.
37. Los G, Mutsaers PH, Lenglet WJ, Baldew GS, McVie JG. Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. Cancer Chemotherapy and Pharmacology 1990;25(6):389-94.
38. Makhija S, Leitao M, Sabbatini P, Bellin N, Almadrones L, Leon L, et al. Complications associated with intraperitoneal chemotherapy catheters. Gynecologic Oncology 2001;81(1):77-81.
39. Markman M. IP chemotherapy. Critical Reviews in Oncology/Hematology 1999;31:239-46.
40. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III. trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III. ovarian cancer: a Gynecologic Oncology Group study. Journal of Clinical Oncology 2003;21(17):3194-200.
41. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17:2815-34.
42. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
43. Weisberger AS, Levine B, Storaasli JP. Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. JAMA 1955;159(18):1704-7.
44. Wenzel LB, Huang H, Armstrong D, Walker J, Cella D. Quality of life (QOL) results of a randomised study of intravenous (IV) paclitaxel and cisplatin vs IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III. epithelial ovarian cancer (OC): A Gynecologic Oncology Group trial. Journal of Clinical Oncology 2004;22(14S):5026.
45. Wenzel LB, Huang HQ, Armstrong DK, Walker JL, Cella D, and Gynecologic Oncology Group. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology 2007;25(4):437-43.
46. Zeimet AG, Reimer D, Radl AC, Reinthaller A, Schauer C, Petru E, et al. Review: Pros and cons of intraperitoneal chemotherapy in the treatment of epithelial ovarian cancer. Anticancer Research 2009;29(7):2803-8.
47. Jaaback K, Johnson N. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD005340.pub2]